NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.
Medication abortion, with a combination of mifepristone and misoprostol, is highly effective and safe. However, there is insufficient evidence on efficacy and safety at very early gestations before a ...
LONDON (Reuters) - About 1,500 of the initial volunteers in a late-stage clinical trial of the Oxford/AstraZeneca COVID-19 vaccine were given the wrong dose, but weren't informed that a mistake had ...
Successful completion of chemotherapy is critical to improve breast cancer outcomes. Relative dose intensity (RDI), defined as the ratio of chemotherapy delivered to prescribed, is a measure of ...
Hosted on MSN
A randomized trial of mexiletine and lamotrigine in adults with non-dystrophic myotonia
The study, published in Lancet Neurology, detailed the "head-to-head" trial implemented by the researchers to test two drugs, mexiletine and lamotrigine, on people with the condition. The trial, which ...
Twice-yearly mass distribution of azithromycin to children is a promising intervention to reduce childhood mortality in sub-Saharan Africa. The World Health Organization recommended restricting ...
In order to provide gender-affirming care, clinicians must sometimes jump through unusual hoops. In Australia, for example, the government won’t subsidize testosterone treatment for a trans man ...
Limited evidence has suggested that metformin could reduce some of the pathology underlying osteoarthritis (OA). Researchers conducted a small randomized trial to assess metformin's effectiveness in ...
LUND, Sweden, May 31, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ Stockholm: HNSA), today announced recruitment and randomization in its US ConfIdeS trial is complete.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback